[{"id":"c121533e-47d9-4ac4-9593-e7db6d83a51b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06970132","created_at":"2025-09-07T01:34:43.364Z","updated_at":"2025-09-07T01:34:43.364Z","phase":"Phase 1/2","brief_title":"Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT06970132","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e conteltinib (SY-707) • SY-5933"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-05-14"},{"id":"d49f879c-07fe-44a8-91c1-8d378e8089b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02695550","created_at":"2021-01-18T13:09:30.898Z","updated_at":"2024-07-02T16:37:24.543Z","phase":"Phase 1","brief_title":"Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02695550","lead_sponsor":"Centaurus Biopharma Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • conteltinib (SY-707)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2017-03-09"}]